08:56 AM EST - Oncolytics Biotech Inc : Announced that the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study following their review of initial safety data. Enrollment in this cohort will resume pending final approval from the Paul Ehrlich Institute (PEI), Germany's medical regulatory body. Additional updates are expected in 2025, with safety data anticipated in the first half and initial efficacy results in the second half. Oncolytics Biotech Inc
shares T.ONC are trading off $0.05 at $1.27.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=4956523604452457
